GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ConvaTec Group PLC (LSE:CTEC) » Definitions » EV-to-EBITDA

ConvaTec Group (LSE:CTEC) EV-to-EBITDA : 17.13 (As of May. 21, 2024)


View and export this data going back to 2016. Start your Free Trial

What is ConvaTec Group EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ConvaTec Group's enterprise value is £6,171 Mil. ConvaTec Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was £360 Mil. Therefore, ConvaTec Group's EV-to-EBITDA for today is 17.13.

The historical rank and industry rank for ConvaTec Group's EV-to-EBITDA or its related term are showing as below:

LSE:CTEC' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.38   Med: 17.85   Max: 31.93
Current: 17.13

During the past 11 years, the highest EV-to-EBITDA of ConvaTec Group was 31.93. The lowest was 9.38. And the median was 17.85.

LSE:CTEC's EV-to-EBITDA is ranked worse than
52.16% of 487 companies
in the Medical Devices & Instruments industry
Industry Median: 16.36 vs LSE:CTEC: 17.13

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-21), ConvaTec Group's stock price is £2.544. ConvaTec Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was £0.049. Therefore, ConvaTec Group's PE Ratio for today is 51.92.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


ConvaTec Group EV-to-EBITDA Historical Data

The historical data trend for ConvaTec Group's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ConvaTec Group EV-to-EBITDA Chart

ConvaTec Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.71 15.25 15.44 20.42 16.58

ConvaTec Group Semi-Annual Data
Dec13 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.44 - 20.42 - 16.58

Competitive Comparison of ConvaTec Group's EV-to-EBITDA

For the Medical Instruments & Supplies subindustry, ConvaTec Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ConvaTec Group's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ConvaTec Group's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where ConvaTec Group's EV-to-EBITDA falls into.



ConvaTec Group EV-to-EBITDA Calculation

ConvaTec Group's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=6170.824/360.305
=17.13

ConvaTec Group's current Enterprise Value is £6,171 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ConvaTec Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was £360 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ConvaTec Group  (LSE:CTEC) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

ConvaTec Group's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.544/0.049
=51.92

ConvaTec Group's share price for today is £2.544.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ConvaTec Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was £0.049.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


ConvaTec Group EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of ConvaTec Group's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


ConvaTec Group (LSE:CTEC) Business Description

Traded in Other Exchanges
Address
23 Forbury Road, 3 Forbury Place, Reading, GBR, RG1 3JH
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and continence care are the largest divisions, accounting for 30% and 26% of total revenue, respectively. Ostomy contributes 25% of revenue and infusion sets 19%.

ConvaTec Group (LSE:CTEC) Headlines